Portfolio
Investing in the Future of Human Health
Healthcare innovation represents one of the most compelling long-term investment opportunities. We partner with pioneers developing the next generation of life-changing therapies.
Science-Led Investing
Deep therapeutic expertise meets institutional rigour
Our investment team includes former physicians, research scientists, and regulatory specialists who evaluate clinical viability, intellectual property strength, and commercial potential at every stage.
We invest across therapeutic areas and development stages, managing binary trial risk through disciplined portfolio construction and deep scientific due diligence.
Investment Pipeline
Active portfolio across every stage of development
Discovery
Pre-Clinical
Phase I
Phase II
Phase III
Approved
Investment Focus Areas
Biotechnology
Growth-stage biotech companies developing novel therapeutics, vaccines, and diagnostics targeting significant unmet medical need across oncology, immunology, and rare disease.
Medical Devices
Innovative medtech platforms improving clinical outcomes through minimally invasive procedures, robotic surgery, and next-generation implantable technologies.
Genomics & Precision Medicine
Next-generation sequencing, gene therapy, and personalised medicine platforms reshaping how we diagnose, treat, and prevent disease at the molecular level.
Digital Health
AI-powered diagnostics, remote patient monitoring, and software platforms transforming healthcare delivery, access, and cost efficiency at scale.
"The convergence of biology and technology is creating a once-in-a-generation opportunity to improve human health and generate exceptional returns."
— Dr. Sarah Chen, Head of Life Sciences
$800M
Deployed
32
Companies
3
FDA Approvals
12
Therapeutic Areas